THROMOPAG 25

Share :

Related Products

Introduction

Thromopag 25 is a brand name for eltrombopag, an oral thrombopoietin receptor agonist (TPO-RA). It stimulates platelet production by binding to the thrombopoietin (TPO) receptor on bone marrow megakaryocytes. It is primarily used to treat chronic immune thrombocytopenia (ITP) and other conditions associated with low platelet counts.


Storage

  • Store at room temperature (20–25°C) in a dry place.

  • Keep the tablets in their original blister pack to protect from moisture.

  • Do not refrigerate or freeze.


Use (Indications)

  1. Chronic Immune Thrombocytopenia (ITP) – For adults and children (≥1 year) who have not responded adequately to corticosteroids or immunoglobulins.

  2. Chronic Hepatitis C-Associated Thrombocytopenia – Helps increase platelet counts before antiviral therapy.

  3. Severe Aplastic Anemia (SAA) – Used in combination with immunosuppressive therapy in patients who are ineligible for hematopoietic stem cell transplant.


Clinical Significance

  • Increases platelet counts, reducing the risk of bleeding.

  • Reduces dependency on platelet transfusions and corticosteroids.

  • Improves quality of life in chronic ITP patients.

  • Oral administration (more convenient than injectable alternatives like romiplostim).


Drawbacks

  • High cost (expensive long-term treatment).

  • Requires strict monitoring (risk of excessive platelet increase leading to thrombosis).

  • Not a cure – Platelet counts may drop after discontinuation.

  • Food and drug interactions (must be taken on an empty stomach, avoid calcium-rich foods, and certain medications like antacids).


Side Effects

Common Side Effects Serious Side Effects
– Headache – Thrombosis (blood clots)
– Nausea – Liver toxicity (requires regular LFT monitoring)
– Fatigue – Bone marrow fibrosis (rare, long-term use)
– Diarrhea – Increased risk of cataracts (monitor eye exams)
– Rash – Hematologic malignancies (theoretical risk)

Conclusion

Thromopag 25 (eltrombopag) is an effective oral treatment for chronic ITP, hepatitis C-related thrombocytopenia, and severe aplastic anemia. While it significantly improves platelet counts and reduces bleeding risk, it requires careful monitoring for liver toxicity, thrombosis, and other potential complications. It is a valuable option for patients who do not respond to first-line therapies but must be used under strict medical supervision.

Introduction

Thromopag 25 is a brand name for eltrombopag, an oral thrombopoietin receptor agonist (TPO-RA). It stimulates platelet production by binding to the thrombopoietin (TPO) receptor on bone marrow megakaryocytes. It is primarily used to treat chronic immune thrombocytopenia (ITP) and other conditions associated with low platelet counts.


Storage

  • Store at room temperature (20–25°C) in a dry place.

  • Keep the tablets in their original blister pack to protect from moisture.

  • Do not refrigerate or freeze.


Use (Indications)

  1. Chronic Immune Thrombocytopenia (ITP) – For adults and children (≥1 year) who have not responded adequately to corticosteroids or immunoglobulins.

  2. Chronic Hepatitis C-Associated Thrombocytopenia – Helps increase platelet counts before antiviral therapy.

  3. Severe Aplastic Anemia (SAA) – Used in combination with immunosuppressive therapy in patients who are ineligible for hematopoietic stem cell transplant.


Clinical Significance

  • Increases platelet counts, reducing the risk of bleeding.

  • Reduces dependency on platelet transfusions and corticosteroids.

  • Improves quality of life in chronic ITP patients.

  • Oral administration (more convenient than injectable alternatives like romiplostim).


Drawbacks

  • High cost (expensive long-term treatment).

  • Requires strict monitoring (risk of excessive platelet increase leading to thrombosis).

  • Not a cure – Platelet counts may drop after discontinuation.

  • Food and drug interactions (must be taken on an empty stomach, avoid calcium-rich foods, and certain medications like antacids).


Side Effects

Common Side Effects Serious Side Effects
– Headache – Thrombosis (blood clots)
– Nausea – Liver toxicity (requires regular LFT monitoring)
– Fatigue – Bone marrow fibrosis (rare, long-term use)
– Diarrhea – Increased risk of cataracts (monitor eye exams)
– Rash – Hematologic malignancies (theoretical risk)

Conclusion

Thromopag 25 (eltrombopag) is an effective oral treatment for chronic ITP, hepatitis C-related thrombocytopenia, and severe aplastic anemia. While it significantly improves platelet counts and reduces bleeding risk, it requires careful monitoring for liver toxicity, thrombosis, and other potential complications. It is a valuable option for patients who do not respond to first-line therapies but must be used under strict medical supervision.

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions – 

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Introduction

Thromopag 25 is a brand name for eltrombopag, an oral thrombopoietin receptor agonist (TPO-RA). It stimulates platelet production by binding to the thrombopoietin (TPO) receptor on bone marrow megakaryocytes. It is primarily used to treat chronic immune thrombocytopenia (ITP) and other conditions associated with low platelet counts.


Storage

  • Store at room temperature (20–25°C) in a dry place.

  • Keep the tablets in their original blister pack to protect from moisture.

  • Do not refrigerate or freeze.


Use (Indications)

  1. Chronic Immune Thrombocytopenia (ITP) – For adults and children (≥1 year) who have not responded adequately to corticosteroids or immunoglobulins.

  2. Chronic Hepatitis C-Associated Thrombocytopenia – Helps increase platelet counts before antiviral therapy.

  3. Severe Aplastic Anemia (SAA) – Used in combination with immunosuppressive therapy in patients who are ineligible for hematopoietic stem cell transplant.


Clinical Significance

  • Increases platelet counts, reducing the risk of bleeding.

  • Reduces dependency on platelet transfusions and corticosteroids.

  • Improves quality of life in chronic ITP patients.

  • Oral administration (more convenient than injectable alternatives like romiplostim).


Drawbacks

  • High cost (expensive long-term treatment).

  • Requires strict monitoring (risk of excessive platelet increase leading to thrombosis).

  • Not a cure – Platelet counts may drop after discontinuation.

  • Food and drug interactions (must be taken on an empty stomach, avoid calcium-rich foods, and certain medications like antacids).


Side Effects

Common Side Effects Serious Side Effects
– Headache – Thrombosis (blood clots)
– Nausea – Liver toxicity (requires regular LFT monitoring)
– Fatigue – Bone marrow fibrosis (rare, long-term use)
– Diarrhea – Increased risk of cataracts (monitor eye exams)
– Rash – Hematologic malignancies (theoretical risk)

Conclusion

Thromopag 25 (eltrombopag) is an effective oral treatment for chronic ITP, hepatitis C-related thrombocytopenia, and severe aplastic anemia. While it significantly improves platelet counts and reduces bleeding risk, it requires careful monitoring for liver toxicity, thrombosis, and other potential complications. It is a valuable option for patients who do not respond to first-line therapies but must be used under strict medical supervision.

Reviews

There are no reviews yet.

Be the first to review “THROMOPAG 25”

Your email address will not be published. Required fields are marked *

Introduction

Thromopag 25 is a brand name for eltrombopag, an oral thrombopoietin receptor agonist (TPO-RA). It stimulates platelet production by binding to the thrombopoietin (TPO) receptor on bone marrow megakaryocytes. It is primarily used to treat chronic immune thrombocytopenia (ITP) and other conditions associated with low platelet counts.


Storage

  • Store at room temperature (20–25°C) in a dry place.

  • Keep the tablets in their original blister pack to protect from moisture.

  • Do not refrigerate or freeze.


Use (Indications)

  1. Chronic Immune Thrombocytopenia (ITP) – For adults and children (≥1 year) who have not responded adequately to corticosteroids or immunoglobulins.

  2. Chronic Hepatitis C-Associated Thrombocytopenia – Helps increase platelet counts before antiviral therapy.

  3. Severe Aplastic Anemia (SAA) – Used in combination with immunosuppressive therapy in patients who are ineligible for hematopoietic stem cell transplant.


Clinical Significance

  • Increases platelet counts, reducing the risk of bleeding.

  • Reduces dependency on platelet transfusions and corticosteroids.

  • Improves quality of life in chronic ITP patients.

  • Oral administration (more convenient than injectable alternatives like romiplostim).


Drawbacks

  • High cost (expensive long-term treatment).

  • Requires strict monitoring (risk of excessive platelet increase leading to thrombosis).

  • Not a cure – Platelet counts may drop after discontinuation.

  • Food and drug interactions (must be taken on an empty stomach, avoid calcium-rich foods, and certain medications like antacids).


Side Effects

Common Side Effects Serious Side Effects
– Headache – Thrombosis (blood clots)
– Nausea – Liver toxicity (requires regular LFT monitoring)
– Fatigue – Bone marrow fibrosis (rare, long-term use)
– Diarrhea – Increased risk of cataracts (monitor eye exams)
– Rash – Hematologic malignancies (theoretical risk)

Conclusion

Thromopag 25 (eltrombopag) is an effective oral treatment for chronic ITP, hepatitis C-related thrombocytopenia, and severe aplastic anemia. While it significantly improves platelet counts and reduces bleeding risk, it requires careful monitoring for liver toxicity, thrombosis, and other potential complications. It is a valuable option for patients who do not respond to first-line therapies but must be used under strict medical supervision.

Reviews

There are no reviews yet.

Be the first to review “THROMOPAG 25”

Your email address will not be published. Required fields are marked *

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.
Scroll to Top

Log in

Create an Account

Send Enquiry For THROMOPAG 25